<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632448</url>
  </required_header>
  <id_info>
    <org_study_id>ESPS-001</org_study_id>
    <nct_id>NCT02632448</nct_id>
  </id_info>
  <brief_title>A Study of LY2880070 in Participants With Advanced or Metastatic Cancer</brief_title>
  <official_title>A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Esperas Pharma Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Esperas Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this two-part study is to evaluate the safety and efficacy of the study&#xD;
      drug known as LY2880070 in participants with advanced or metastatic solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">March 27, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose(s)</measure>
    <time_frame>Baseline through Cycle 1 (Estimated up to 21 days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dose limiting toxicities (DLTs)</measure>
    <time_frame>Baseline through Cycle 1 (Estimated up to 21 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve from time zero to 24 hours post-dose (AUC0-24)</measure>
    <time_frame>Baseline to 24-hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax)</measure>
    <time_frame>Baseline to 24 hours post-dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax)</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in white blood cell count</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in neutrophil count</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lymphocyte count</measure>
    <time_frame>Baseline to 24 hours post dose (up to Day 20 in Cycle 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with tumor response (objective response rate) as measured by the Response Evaluable Criteria in Solid Tumors (RECIST v.1.1)</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of objective response</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Baseline to study completion (estimated up to 4 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Baseline up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Rectal Cancer</condition>
  <condition>Neoplasms</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Pancreas Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part A: LY2880070</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY2880070 with Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070, and Gemcitabine administered intravenously during 21-day cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY2880070 (Metabolism Phenotype)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 administered during 21 day cycles, to participants who are poor metabolizers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Breast)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Colorectal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B:LY2880070 and Gemcitabine (Ovarian)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Endometrial)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Pancreatic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of LY2880070 during 21-day cycles with Gemcitabine (administered intravenously)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2880070</intervention_name>
    <description>Capsules</description>
    <arm_group_label>Part A: LY2880070</arm_group_label>
    <arm_group_label>Part A: LY2880070 (Metabolism Phenotype)</arm_group_label>
    <arm_group_label>Part A: LY2880070 with Gemcitabine</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Breast)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Colorectal)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Endometrial)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Pancreatic)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))</arm_group_label>
    <arm_group_label>Part B:LY2880070 and Gemcitabine (Ovarian)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>50 to 600 milligrams per square meter of body surface area (mg/m2)</description>
    <arm_group_label>Part A: LY2880070 with Gemcitabine</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Breast)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Colorectal)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Endometrial)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Pancreatic)</arm_group_label>
    <arm_group_label>Part B: LY2880070 and Gemcitabine (Soft Tissue Sarcoma (STS))</arm_group_label>
    <arm_group_label>Part B:LY2880070 and Gemcitabine (Ovarian)</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             scale&#xD;
&#xD;
          -  Have an estimated life expectancy of greater than or equal to (≥)12 weeks&#xD;
&#xD;
          -  Have adequate organ function&#xD;
&#xD;
          -  Have received 1-4 prior systemic therapies for locally advanced or metastatic disease&#xD;
&#xD;
          -  Agree to use medically approved contraceptives during the study and for 3 months&#xD;
             following the last study treatment&#xD;
&#xD;
          -  All females must have a negative serum pregnancy test result, and females of&#xD;
             child-bearing potential must have a negative urine pregnancy test result, prior to the&#xD;
             first study treatment&#xD;
&#xD;
          -  Have tumor lesions considered measurable by the Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) v1.1&#xD;
&#xD;
          -  Must be, in the judgment of the investigator, an appropriate candidate for&#xD;
             experimental therapy, and no standard therapy would confer clinical benefit&#xD;
&#xD;
        For Part A&#xD;
&#xD;
          -  Must have evidence of cancer (solid tumors, excluding glioblastoma and primary brain&#xD;
             tumor) that is advanced or metastatic&#xD;
&#xD;
          -  For the Metabolism Phenotype Arm in Part A, participants must have a Cytochrome P450&#xD;
             (CYP2D6) poor metabolizer phenotype&#xD;
&#xD;
        For Part B&#xD;
&#xD;
          -  Have advanced or metastatic colorectal cancer, triple negative breast cancer (per&#xD;
             American Society of Clinical Oncology-College of American Pathology guidelines),&#xD;
             epithelial ovarian cancer, endometrial, soft tissue sarcoma, pancreatic cancer&#xD;
&#xD;
               -  For TNBC:&#xD;
&#xD;
                    -  Recurrent/refractory Triple Negative Breast Cancer (TNBC) defined as any&#xD;
                       beast cancer that expresses &lt;1% estrogen receptor (ER) and &lt;1% progesterone&#xD;
                       receptor (PR) and is Her2 negative&#xD;
&#xD;
               -  For Colorectal (CRC):&#xD;
&#xD;
                    -  Must have histologically confirmed advanced or metastatic colorectal cancer&#xD;
&#xD;
               -  For Ovarian Cancer:&#xD;
&#xD;
                    -  Must have histologically confirmed advanced or metastatic epithelial ovarian&#xD;
                       cancer&#xD;
&#xD;
                    -  Must be eligible to receive Gemzar (GEM) and not refractory to&#xD;
                       GEM/carboplatin&#xD;
&#xD;
                    -  Must have the ability to tolerate GEM&#xD;
&#xD;
                    -  May have received GEM as previous therapy&#xD;
&#xD;
               -  For Endometrial cancer:&#xD;
&#xD;
                    -  Must have histologically confirmed endometrial cancer that is metastatic or&#xD;
                       locally advanced&#xD;
&#xD;
                    -  Must have failed at least 1 prior chemotherapy&#xD;
&#xD;
               -  For STS:&#xD;
&#xD;
                    -  Must have histologically confirmed STS that is metastatic or locally&#xD;
                       advanced&#xD;
&#xD;
                    -  Patients with gastrointestinal stromal tumors (GIST) must have failed a KIT&#xD;
                       inhibitor&#xD;
&#xD;
                    -  Must have failed at least 1 prior chemotherapy&#xD;
&#xD;
               -  For Pancreatic Cancer:&#xD;
&#xD;
                    -  Must have histologically confirmed pancreatic cancer that is metastatic or&#xD;
                       locally advanced&#xD;
&#xD;
                    -  Must have failed at least 1 prior chemotherapy regimen&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received treatment with an investigational drug which has not received regulatory&#xD;
             approval within 21 days of first study treatment&#xD;
&#xD;
          -  Have symptomatic central nervous system (CNS) metastasis&#xD;
&#xD;
          -  Females who are pregnant or nursing&#xD;
&#xD;
          -  Have known positive test results of human immunodeficiency virus, or have chronic&#xD;
             active hepatitis A, B or C&#xD;
&#xD;
          -  Have a corrected QT interval (QTcB) greater than (&gt;) 470 milliseconds (msec) (female)&#xD;
             or &gt;450 msec (male), or a history of congenital long QT syndrome&#xD;
&#xD;
          -  Have had a bone marrow transplant&#xD;
&#xD;
          -  Have participated in this study, or are currently enrolled in another clinical study&#xD;
             of an investigational medicinal product&#xD;
&#xD;
          -  Have had radiation therapy to &gt;25% of bone marrow&#xD;
&#xD;
          -  For Part B&#xD;
&#xD;
               -  Have a history of another active cancer within the past year, except cervical&#xD;
                  cancer in situ, in situ carcinoma of the bladder, basal cell carcinoma of the&#xD;
                  skin, or another in situ carcinoma that is considered cured&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: choruspharma@lists.lilly.com</last_name>
    <role>Study Director</role>
    <affiliation>Esperas Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esperas Pharma Inc.</last_name>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffrey Shapiro</last_name>
      <phone>877-338-7425</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jas Grewal-Karwa</last_name>
      <phone>313-576-8932</phone>
      <email>karwaj@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Shields</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnie Chalmers</last_name>
      <phone>(780) 432-8248</phone>
      <email>Bonnie.Chalmers@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Quincy Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Health Network - Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Oza</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2818</phone_ext>
    </contact>
    <investigator>
      <last_name>Amit Oza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilson Miller</last_name>
      <phone>514-340-8222</phone>
    </contact>
    <investigator>
      <last_name>Wilson Miller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Provencher</last_name>
      <phone>514-890-8444</phone>
      <email>diane.provencher.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Diane Provencher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic cancer</keyword>
  <keyword>Advanced cancer</keyword>
  <keyword>Recurrent cancer</keyword>
  <keyword>Colorectal neoplasms</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Ovarian neoplasms</keyword>
  <keyword>Colon neoplasms</keyword>
  <keyword>Rectal neoplasms</keyword>
  <keyword>Triple negative breast neoplasms</keyword>
  <keyword>Gastrointestinal stromal tumor</keyword>
  <keyword>Pancreatic Neoplasms</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

